Services

Toxicology

Pharmacology

Animal Model Development

Medical Device Testing

In Vitro Screening

Custom Assay Development

Vivarium Rental

Histology

Therapeutic Areas

Oncology

Immunology & Inflammation

Neurology / CNS

Cardiovascular

Dermatology & Wound Healing

Metabolism

Gastroenterology

Hepatology

Pulmonology

Infectious Diseases & Sepsis

Musculoskeletal

Nephrology & Urology

Species

Non-human Primates

Dogs

Mini-Pigs / Pigs

Rabbits

Mice

Rats

Sheep

Guinea Pigs

Hamsters

Other Species

Capabilities

GLP / IND-Enabling Studies

Small and Large Animal Housing

Bioanalytical Platforms

About

News

Contact

Careers

Request a Quote

Logo
☰
  • Services ⌄
    • Toxicology
    • Pharmacology
    • Animal Model Development
    • Medical Device Testing
    • In Vitro Screening
    • Custom Assay Development
    • Vivarium Rental
    • Histology
  • Therapeutic Areas ⌄
    • Oncology
    • Immunology & Inflammation
    • Neurology / CNS
    • Cardiovascular
    • Dermatology & Wound Healing
    • Metabolism
    • Gastroenterology
    • Hepatology
    • Pulmonology
    • Infectious Diseases & Sepsis
    • Musculoskeletal
    • Nephrology & Urology
  • Species ⌄
    • Non-human Primates
    • Dogs
    • Mini-Pigs / Pigs
    • Rabbits
    • Mice
    • Rats
    • Sheep
    • Guinea Pigs
    • Hamsters
    • Other Species
  • Capabilities ⌄
    • GLP / IND-Enabling Studies
    • Small and Large Animal Housing
    • Bioanalytical Platforms
  • About ⌄
    • News
  • Contact ⌄
    • Careers
    • Request a Quote

Europe's NeuroSearch Exploring Sale, Possible Liquidation of Company in the Next Few Months

  • Post author:Sam
  • Post published:December 4, 2017
  • Post category:BioPharma

The Board of Directors also stated that it would endeavour to have a final clarification of the Company’s future by the end of 2017. Source: BioSpace

Continue ReadingEurope's NeuroSearch Exploring Sale, Possible Liquidation of Company in the Next Few Months

4 Solid Biotechs to Load Up on This Month

  • Post author:Sam
  • Post published:December 3, 2017
  • Post category:BioPharma

Barring a huge meltdown, the S&P 500 will once again have a double-digit year of gains, and most investors should be looking at their 401(k)s and other accounts with some…

Continue Reading4 Solid Biotechs to Load Up on This Month

Sanofi's Bad End-of-the-Year Continues With Axing of Its C. Diff Drug

  • Post author:Sam
  • Post published:December 3, 2017
  • Post category:BioPharma

Sanofi terminated an experimental Clostridium difficile vaccine after an Independent Data Monitoring Committee concluded the Phase III trial was unlikely to hit its endpoints. Source: BioSpace

Continue ReadingSanofi's Bad End-of-the-Year Continues With Axing of Its C. Diff Drug

AstraZeneca Investors Rejoice After COPD Drug Performs in Phase IV Study

  • Post author:Sam
  • Post published:December 3, 2017
  • Post category:BioPharma

Tudorza, also marketed as Eklira and Bretaris, is available in more than 50 countries. Source: BioSpace

Continue ReadingAstraZeneca Investors Rejoice After COPD Drug Performs in Phase IV Study

The Philippines Suspends Sanofi's Dengue Vaccine After 730,000+ Children are Immunized

  • Post author:Sam
  • Post published:December 3, 2017
  • Post category:BioPharma

Sanofi said the analysis showed more cases of severe disease could occur following vaccination in patients who had not been previously infected by the dengue virus. Source: BioSpace

Continue ReadingThe Philippines Suspends Sanofi's Dengue Vaccine After 730,000+ Children are Immunized

Amgen on a Roll as the FDA OKs Repatha to Prevent Heart Attack and Stroke

  • Post author:Sam
  • Post published:December 3, 2017
  • Post category:BioPharma

Following FDA priority review, Repatha is the only PCSK9 inhibitor approved to reduce risk of heart attack, stroke and coronary revascularization. Source: BioSpace

Continue ReadingAmgen on a Roll as the FDA OKs Repatha to Prevent Heart Attack and Stroke

2 Bay Area Biotechs Expected to Grow 67% or Up Over the Next Five Years

  • Post author:Sam
  • Post published:December 3, 2017
  • Post category:BioPharma

A look at two life science companies that are expected to grow more than 67 percent over the next five years. Source: BioSpace

Continue Reading2 Bay Area Biotechs Expected to Grow 67% or Up Over the Next Five Years

Little Idorsia Scores $230M+ R&D Deal With Johnson & Johnson

  • Post author:Sam
  • Post published:December 3, 2017
  • Post category:BioPharma

Today, Janssen Biotech announced it had exercised its option to enter into a collaboration deal with Idorsia to jointly develop and market aprocitentan and any derivative compounds. Source: BioSpace

Continue ReadingLittle Idorsia Scores $230M+ R&D Deal With Johnson & Johnson

Longtime Seattle Genetics COO Jumps Ship to Helm Biotech Startup Silverback Therapeutics

  • Post author:Sam
  • Post published:December 3, 2017
  • Post category:BioPharma

The COO of Seattle Genetics, Eric Dobmeier, is leaving the company to helm Silverback Therapeutics. Source: BioSpace

Continue ReadingLongtime Seattle Genetics COO Jumps Ship to Helm Biotech Startup Silverback Therapeutics

Gilead Commits $100M to Tackle the HIV/AIDS Epidemic in the Southern U.S.

  • Post author:Sam
  • Post published:December 3, 2017
  • Post category:BioPharma

Gilead will partner with three coordinating centers to lead the corporate giving program of the initiative. Source: BioSpace

Continue ReadingGilead Commits $100M to Tackle the HIV/AIDS Epidemic in the Southern U.S.
  • Go to the previous page
  • 1
  • …
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • …
  • 288
  • Go to the next page

Stay Connected

Keep up with the latest news & insights.

Contact Us

Phone:
+1 858-605-5882
Fax:
+1 858-605-5916
Email:
info@biolegacyresearch.com
Mail:

6042 Cornerstone Court W

Suite E

San Diego, CA 92121

Social:
© 2025 BioLegacy Research. All rights reserved.